Zobrazeno 1 - 10
of 8 035
pro vyhledávání: '"Novotny W"'
Autor:
Michael A. Choti
Publikováno v:
Cancer Treatment Reviews. 30:715-720
Autor:
Soumerai JD; Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA., Diefenbach CS; Perlmutter Cancer Center at NYU Langone Health, New York, New York, USA., Jagadeesh D; Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, Ohio, USA., Asch A; Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA., Kumar A; University of Arizona, Tucson, Arizona, USA., Tsai ML; Swedish Cancer Institute, Seattle, Washington, USA., Jandl TA; Stony Brook University Hospital, Stony Brook, New York, USA., Lossos IS; Sylvester Comprehensive Cancer Center, University of Miami School of Medicine, Miami, Florida, USA., Kenkre VP; Carbone Cancer Center, University of Wisconsin, Madison, Wisconsin, USA., Awan F; University of Texas Southwestern Medical Center, Dallas, Texas, USA., Novotny W; BeiGene, LTD, Cambridge, Massachusetts, USA., Huang J; BeiGene, LTD, Cambridge, Massachusetts, USA., Miao L; MEI Pharma, Inc., San Diego, California, USA., Rajagopalan P; PR Consulting, Mountain Lakes, New Jersey, USA., Ghalie RG; MEI Pharma, Inc., San Diego, California, USA., Zelenetz AD; Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Publikováno v:
British journal of haematology [Br J Haematol] 2024 May; Vol. 204 (5), pp. 1762-1770. Date of Electronic Publication: 2024 Mar 19.
Autor:
Guo, R., Dowlati, A., Dagogo-Jack, I., Vibert, J., Spira, A.I., Moreno Garcia, V., Punekar, S., Calvo, E., Sonpavde, G.P., Awad, M., Riess, J.W., Hernandez Guerrero, T.C., Herzberg, B., Italiano, A., Swalduz, A., Lorusso, P., Smit, E.F., Garon, E.B., Novotny, W., Yap, T.A.
Publikováno v:
In Annals of Oncology September 2024 35 Supplement 2:S483-S484
Autor:
Bachy E; Hematology Department, Lyon Sud Hospital and Claude Bernard Lyon 1 University, Lyon, France., Savage KJ; Division of Medical Oncology, University of British Columbia, BC Cancer, Vancouver, Canada., Huang H; Sun Yat-Sen University Cancer Center, Guangzhou, China., Kwong YL; Queen Mary Hospital, Hong Kong SAR, China., Gritti G; ASST Papa Giovanni XXIII, Bergamo, Italy., Zhang Q; Harbin Medical University Cancer Hospital, Harbin, China., Liberati AM; Azienda Ospedaliera Santa Maria Terni, Terni, Italy., Cao J; Fudan University Shanghai Cancer Center, Shanghai, China., Yang H; The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, China., Hao S; Xin Hua Hospital, Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China., Hu J; Fujian Medical University Union Hospital, Fujian Institute of Hematology, Fuzhou, China., Zhou K; Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China., Petrini M; Azienda Ospedaliero Universitaria Pisana, Stabilimento di Santa Chiara, Pisa, Italy., Russo F; Ospedale Maggiore, Ematologia e Centro Trapianti Midollo Osseo (CTMO), AOU Parma, Parma, Italy., Zhang H; Tianjin Medical University Cancer Institute & Hospital, Tianjin, China., Sang W; The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China., Ji J; West China Hospital, Sichuan University, Chengdu, China., Ferreri AJM; Lymphoma Unit, IRCCS San Raffaele Scientific Institute, Milano, Italy., Damaj GL; Institut d'Hematologie de Basse Normandie, Caen, France., Liu H; Beijing Hospital, Beijing, China., Zhang W; Peking Union Medical College Hospital, Beijing, China., Ke X; Peking University Third Hospital, Beijing, China., Ghiggi C; Ospedale Policlinico San Martino, Genoa, Italy., Huang S; BeiGene (Shanghai) Co Ltd, Shanghai, China., Li X; BeiGene (Shanghai) Co Ltd, Shanghai, China., Yao H; BeiGene (Shanghai) Co Ltd, Shanghai, China., Paik J; BeiGene USA, Inc, San Mateo, CA., Novotny W; BeiGene USA, Inc, San Mateo, CA., Zhou W; BeiGene (Shanghai) Co Ltd, Shanghai, China., Zhu H; BeiGene (Shanghai) Co Ltd, Shanghai, China., Zinzani PL; IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia 'Seràgnoli,' Bologna, Italy.; Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università di Bologna, Bologna, Italy.
Publikováno v:
Blood advances [Blood Adv] 2023 Aug 22; Vol. 7 (16), pp. 4435-4447.
Zanubrutinib is a selective Bruton tyrosine kinase (BTK) inhibitor evaluated in multiple B-cell malignancy studies. We constructed a pooled safety analysis to better understand zanubrutinib-associated treatment-emergent adverse events (TEAEs) and ide
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______2127::382e8026fad8f9ee911409c15eb0c27c
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3100383
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3100383
Autor:
Tam CS; The Alfred Hospital, Monash University, Melbourne, VIC, Australia., Trotman J; Concord Repatriation General Hospital, Concord, NSW, Australia.; The University of Sydney, Concord, NSW, Australia., Opat S; Monash Health, Clayton, VIC, Australia.; Monash University, Clayton, VIC, Australia., Stern JC; BeiGene, San Mateo, CA., Allewelt H; BeiGene, San Mateo, CA., By K; BeiGene, San Mateo, CA., Novotny W; BeiGene, San Mateo, CA., Huang J; BeiGene, San Mateo, CA., Tedeschi A; ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy.
Publikováno v:
Blood advances [Blood Adv] 2023 Jun 27; Vol. 7 (12), pp. 2884-2887.
Autor:
Xu W; Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Collaborative Innovation Center for Personalized Cancer Medicine, Nanjing, China., Yang S; Peking University Peoples Hospital, Peking University Institute of Hematology, Beijing, China., Zhou K; Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China., Pan L; West China Hospital of Sichuan University, Chengdu, China., Li Z; Blood Disease Hospital, Chinese Academy of Medical Science, Tianjin, China., Gao S; The First Hospital of Jilin University, Changchun, China., Zhou D; Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China., Hu J; Fujian Provincial Key Laboratory on Hematology, Fujian Institute of Hematology, Fujian Medical University Union Hospital, Fuzhou, China., Feng R; Nanfang Hospital of Southern Medical University, Guangzhou, China., Huang H; The First Hospital of Soochow University, Suzhou, China., Wang T; Blood Disease Hospital, Chinese Academy of Medical Science, Tianjin, China., Li D; Tongji Hospital, Tongji Medical College, Wuhan, China., Ji M; BeiGene (Beijing) Co., Ltd., Beijing, China.; BeiGene (Shanghai) Co., Ltd., Shanghai, China.; BeiGene USA, Inc., San Mateo, CA, USA., Guo H; BeiGene (Beijing) Co., Ltd., Beijing, China.; BeiGene (Shanghai) Co., Ltd., Shanghai, China.; BeiGene USA, Inc., San Mateo, CA, USA., Zhao X; BeiGene (Beijing) Co., Ltd., Beijing, China.; BeiGene (Shanghai) Co., Ltd., Shanghai, China.; BeiGene USA, Inc., San Mateo, CA, USA., Wu B; BeiGene (Beijing) Co., Ltd., Beijing, China.; BeiGene (Shanghai) Co., Ltd., Shanghai, China.; BeiGene USA, Inc., San Mateo, CA, USA., Yu Y; BeiGene (Beijing) Co., Ltd., Beijing, China.; BeiGene (Shanghai) Co., Ltd., Shanghai, China.; BeiGene USA, Inc., San Mateo, CA, USA., Wang Y; BeiGene (Beijing) Co., Ltd., Beijing, China.; BeiGene (Shanghai) Co., Ltd., Shanghai, China.; BeiGene USA, Inc., San Mateo, CA, USA., Huang J; BeiGene (Beijing) Co., Ltd., Beijing, China.; BeiGene (Shanghai) Co., Ltd., Shanghai, China.; BeiGene USA, Inc., San Mateo, CA, USA., Novotny W; BeiGene (Beijing) Co., Ltd., Beijing, China.; BeiGene (Shanghai) Co., Ltd., Shanghai, China.; BeiGene USA, Inc., San Mateo, CA, USA., Li J; Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Collaborative Innovation Center for Personalized Cancer Medicine, Nanjing, China.
Publikováno v:
Leukemia & lymphoma [Leuk Lymphoma] 2023 Mar; Vol. 64 (3), pp. 712-716. Date of Electronic Publication: 2023 Feb 17.
Autor:
Tariq B; Clinical Pharmacology, BeiGene USA, Inc, Fulton, MD, USA., Ou YC; Clinical Pharmacology, BeiGene USA, Inc, San Mateo, CA, USA., Stern JC; Clinical Pharmacology, BeiGene USA, Inc, San Mateo, CA, USA., Mundra V; Clinical Pharmacology, BeiGene USA, Inc, San Mateo, CA, USA., Wong Doo N; Department of Hematology, Concord Repatriation General Hospital, Concord, Australia.; Concord Clinical School, University of Sydney, Sydney, Australia., Walker P; Department of Hematology, Peninsula Health and Peninsula Private Hospitals, Frankston, Australia., Lewis KL; Department of Haematology, Sir Charles Gairdner Hospital and Linear Clinical Research, Nedlands, Australia., Lin C; Biostatistics, BeiGene, Ltd, Emeryville, CA, USA., Novotny W; Clinical Development, Hematology, BeiGene USA, Inc, San Mateo, CA, USA., Sahasranaman S; Clinical Pharmacology, BeiGene USA, Inc, San Mateo, CA, USA., Opat S; Clinical Hematology, Monash Health and Monash University, Clayton, Australia.
Publikováno v:
Leukemia & lymphoma [Leuk Lymphoma] 2023 Feb; Vol. 64 (2), pp. 329-338. Date of Electronic Publication: 2022 Dec 08.
Autor:
Dagogo-Jack, I., Dowlati, A., Guo, R., Awad, M.M., Swalduz, A., Calvo, E., Moreno Garcia, V., Adjei, A.A., Lorusso, P., Punekar, S., Leal, T.A., Yap, T.A., Italiano, A., Novotny, W., Tankersley, C., Rowe, S., Paris, G., Sun, W., Spira, A.I., Besse, B.
Publikováno v:
In Annals of Oncology October 2023 34 Supplement 2:S493-S494
Autor:
Mu S; Clinical Pharmacology, BeiGene USA, 2955 Campus Drive, Suite 300, San Mateo, CA, 94403, USA., Tang Z; Clinical Pharmacology, BeiGene USA, 2955 Campus Drive, Suite 300, San Mateo, CA, 94403, USA., Novotny W; Clinical Development, BeiGene USA, San Mateo, CA, USA., Tawashi M; Clinical Operations, BeiGene USA, San Mateo, CA, USA., Li TK; Drug Safety and Pharmacovigilance, BeiGene USA, San Mateo, CA, USA., Ou Y; Clinical Pharmacology, BeiGene USA, 2955 Campus Drive, Suite 300, San Mateo, CA, 94403, USA., Sahasranaman S; Clinical Pharmacology, BeiGene USA, 2955 Campus Drive, Suite 300, San Mateo, CA, 94403, USA. sri.sahasranaman@beigene.com.
Publikováno v:
Cancer chemotherapy and pharmacology [Cancer Chemother Pharmacol] 2020 Feb; Vol. 85 (2), pp. 391-399. Date of Electronic Publication: 2019 Dec 26.